PepGen Inc. (PEPG)
Largest Insider Buys in Sector
PEPG Stock Price History Chart
PEPG Stock Performance
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the …
Insider Activity of PepGen Inc.
Over the last 12 months, insiders at PepGen Inc. have bought $27.21M and sold $1.04M worth of PepGen Inc. stock.
On average, over the past 5 years, insiders at PepGen Inc. have bought $14.44M and sold $827,860 worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $816.38M.
The last purchase of 2,557,593 shares for transaction amount of $27.21M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑02‑09.
List of Insider Buy and Sell Transactions, PepGen Inc.
| 2024-07-25 | Sale | Chief Medical Officer | 7,571 0.0234% | $18.06 | $136,741 | -51.00% | ||
| 2024-07-24 | Sale | Chief Medical Officer | 201 0.0006% | $18.01 | $3,619 | 0.00% | ||
| 2024-07-18 | Sale | Chief Medical Officer | 12,625 0.0427% | $18.20 | $229,804 | -46.66% | ||
| 2024-07-16 | Sale | Chief Medical Officer | 5,901 0.0194% | $18.00 | $106,247 | -50.69% | ||
| 2024-07-12 | Sale | Chief Medical Officer | 3,288 0.0108% | $18.04 | $59,331 | 0.00% | ||
| 2024-07-02 | Sale | Chief Medical Officer | 37 0.0001% | $18.07 | $669 | 0.00% | ||
| 2024-07-01 | Sale | Chief Medical Officer | 875 0.0029% | $18.01 | $15,760 | 0.00% | ||
| 2024-06-24 | Sale | Chief Medical Officer | 9,260 0.0291% | $18.19 | $168,427 | -50.22% | ||
| 2024-06-12 | Sale | Chief Medical Officer | 1,086 0.0034% | $18.06 | $19,615 | -49.32% | ||
| 2024-06-11 | Sale | Chief Medical Officer | 500 0.0016% | $18.04 | $9,022 | -49.89% | ||
| 2024-06-06 | Sale | SVP, Clinical Development | 1,411 0.0045% | $18.00 | $25,398 | -48.18% | ||
| 2024-06-05 | Sale | SVP, Clinical Development | 7,245 0.0223% | $18.09 | $131,062 | -50.44% | ||
| 2024-05-17 | Sale | SVP, Chem. Mfg & Controls | 10,000 0.0306% | $13.41 | $134,100 | -30.96% | ||
| 2024-02-09 | 2.56M 10.4935% | $10.64 | $27.21M | -19.17% | ||||
| 2023-11-30 | President and CEO | 1,694 0.006% | $4.17 | $7,056 | +115.41% | |||
| 2023-06-08 | Sale | President and CEO | 2,381 0.0098% | $16.04 | $38,188 | -54.91% | ||
| 2023-06-07 | Sale | President and CEO | 8,419 0.0366% | $16.23 | $136,618 | -52.77% | ||
| 2023-06-06 | Sale | President and CEO | 18,150 0.076% | $16.18 | $293,660 | -54.30% | ||
| 2023-06-05 | Sale | President and CEO | 500 0.0022% | $16.06 | $8,028 | -52.58% | ||
| 2023-06-02 | Sale | President and CEO | 1,800 0.0075% | $16.04 | $28,863 | -54.46% |
Insider Historical Profitability
| RA CAPITAL MANAGEMENT, L.P. | 9179273 28.161% | $3.63 | 1 | 0 | ||
| Oxford Science Enterprises plc | 10 percent owner | 4755388 14.589% | $3.63 | 1 | 0 | |
| Shah Rajeev M. | 1302600 3.9962% | $3.63 | 1 | 0 | +7.35% | |
| Deerfield Private Design Fund V, L.P. | 476813 1.4628% | $3.63 | 1 | 0 | +7.35% | |
| KEATING LAURIE | director | 4166 0.0128% | $3.63 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| RA Capital Management, L.P. | $157.14M | 32.98 | 10.69M | +31.45% | +$37.6M | 0.16 | |
| Suvretta Capital Management, LLC | $22.36M | 4.69 | 1.52M | +212.56% | +$15.2M | 0.94 | |
| Frazier Life Sciences Management L P | $22.09M | 4.64 | 1.5M | New | +$22.09M | 1 | |
| Viking Global Investors | $21.79M | 4.57 | 1.48M | 0% | +$0 | 0.01 | |
| Perceptive Advisors | $20.73M | 4.35 | 1.41M | New | +$20.73M | 0.01 |